Literature DB >> 10812727

Excluding polio in areas of inadequate surveillance in the final stages of eradication in China.

E J Hoekstra1, F Chai, X J Wang, X L Zhang, J J Yu, J Bilous.   

Abstract

In 1996, China adopted a virological classification of acute flaccid paralysis (AFP) cases for its surveillance system. Only AFP cases with wild poliovirus in stool specimens are confirmed as polio. Cases with adequate stool specimens that are negative for wild poliovirus are not counted. This paper describes a methodology to rule out poliomyelitis in AFP cases with inadequate stool specimens. National surveillance data were analysed using dot maps to detect clusters of AFP cases with high-risk factors for poliomyelitis. The surveillance system and vaccine coverage were assessed during field investigations. Four clusters of AFP cases were identified, but no poliomyelitis cases. Programmatic failures in the identified high-risk areas included low vaccination rates, poor stool specimen collection and inadequate AFP surveillance. Programme strategies were implemented to correct the identified failures. Use of this methodology provides strong evidence consistent with the absence of wild poliovirus in China.

Entities:  

Keywords:  Asia; China; Delivery Of Health Care; Developing Countries; Diseases; Eastern Asia; Epidemiology; Evaluation; Health; Health Services; Immunization; Monitoring; Poliomyelitis--prevention and control; Primary Health Care; Public Health; Research Report; Vaccination; Viral Diseases

Mesh:

Year:  2000        PMID: 10812727      PMCID: PMC2560709     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  1 in total

1.  Profile of polio-compatible cases in Nigeria, 2006-2016.

Authors:  Abdullahi Walla Hamisu; Faisal Shuaib; Ticha Muluh Johnson; Kehinde Craig; Braka Fiona; Richard Banda; Sisay G Tegegne; Ajiboye Oyetunji; Tesfaye B Erbeto; Peter Nsubuga; Rui Gama Vaz; Ado J G Muhamed; Adamu Usman
Journal:  BMC Public Health       Date:  2018-12-13       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.